Penumbra Gross Profit 2011-2026 | PEN

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:

Raw materials and supplies

Wages of production personnel

Depreciation of equipment

Transportation and warehousing costs (if directly related to production)

Importance for business:

Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales.
Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit.
Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry.
Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.

Reasons for a decline in gross profit:

Increase in raw material and supply costs
Rising production expenses
Price reductions due to competition
Decrease in sales volume
Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Penumbra

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
942 M	755 M	683 M	535 M	475 M	338 M	372 M	293 M	217 M	171 M	124 M	82.8 M	57.9 M	49 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
942 M	49 M	364 M

Quarterly Gross Profit Penumbra

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
240 M	224 M	216 M	200 M	163 M	181 M	178 M	167 M	151 M	-	135 M	134 M	127 M	125 M	120 M	119 M	111 M	94.3 M	90.9 M	64.9 M	88 M	98.1 M	96 M	93.9 M	83.9 M	78.7 M	75 M	72.3 M	66.6 M	63.7 M	54.8 M	50.9 M	47.7 M	46.6 M	42.9 M	41.5 M	39.9 M	36.5 M	33.5 M	27.4 M	26.7 M	23.9 M	20.8 M	20.7 M	17.5 M	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
240 M	17.5 M	95.2 M

Gross Profit of other stocks in the Medical devices industry

Issuer	Gross Profit	Price	% 24h	Market Cap	Country
AxoGen AXGN	167 M	$ 33.06	-0.68 %	$ 1.52 B	USA
EDAP TMS S.A. EDAP	24.4 M	$ 3.87	4.18 %	$ 145 M	France
Establishment Labs Holdings ESTA	146 M	$ 59.71	0.23 %	$ 1.77 B	Costa-rica
Edwards Lifesciences Corporation EW	4.73 B	$ 83.36	0.83 %	$ 48.7 B	USA
GenMark Diagnostics, Inc. GNMK	67.9 M	-	-	$ 1.77 B	USA
Axonics Modulation Technologies AXNX	198 M	-	-	$ 3.31 B	USA
Helius Medical Technologies HSDT	61 K	$ 2.04	-5.79 %	$ 1.24 M	USA
Aziyo Biologics AZYO	6.6 M	-	1.37 %	$ 20.5 M	USA
Acutus Medical AFIB	-3.14 M	-	-26.83 %	$ 2.62 M	USA
Integra LifeSciences Holdings Corporation IART	953 M	$ 9.86	3.25 %	$ 759 M	USA
BioSig Technologies BSGM	229 K	-	37.08 %	$ 85.7 M	USA
Inogen INGN	154 M	$ 6.61	2.88 %	$ 176 M	USA
Allied Healthcare Products AHPI	443 K	-	3.58 %	$ 2.21 M	USA
IRIDEX Corporation IRIX	21.8 M	$ 1.34	1.41 %	$ 21.6 M	USA
IRadimed Corporation IRMD	64.3 M	$ 101.07	-0.7 %	$ 1.29 B	USA
Obalon Therapeutics, Inc. OBLN	584 K	-	-5.86 %	$ 30.6 M	USA
LENSAR LNSR	14.1 M	$ 5.57	-0.18 %	$ 64.2 M	USA
Conformis CFMS	23.2 M	-	-	$ 16.4 M	USA
Delcath Systems DCTH	73.4 M	$ 9.13	-0.76 %	$ 327 M	USA
Medtronic PLC MDT	19.6 B	$ 88.72	0.96 %	$ 114 B	USA
Dynatronics Corporation DYNT	6.01 M	-	14.99 %	$ 929 K	USA
Cardiovascular Systems CSII	173 M	-	0.15 %	$ 844 M	USA
Second Sight Medical Products EYES	500 K	-	-0.97 %	$ 54.4 M	USA
Apollo Endosurgery APEN	42.4 M	-	-	$ 475 M	USA
Orthofix Medical OFIX	566 M	$ 11.9	-0.25 %	$ 471 M	Curacao
Avinger AVGR	2 M	-	-20.74 %	$ 369 K	USA
Outset Medical OM	46.8 M	$ 3.6	1.98 %	$ 54.8 K	USA
CryoLife, Inc. CRY	168 M	-	-4.14 %	$ 702 M	USA
CONMED Corporation CNMD	750 M	$ 36.92	-0.43 %	$ 1.15 B	USA
Insulet Corporation PODD	1.94 B	$ 219.51	1.62 %	$ 15.4 B	USA
Profound Medical Corp. PROF	4.38 M	$ 6.62	13.75 %	$ 180 M	Canada
Quanterix Corporation QTRX	65 M	$ 4.02	1.52 %	$ 171 M	USA
Hancock Jaffe Laboratories, Inc. HJLI	4.25 K	-	-1.98 %	$ 98.3 M	USA
Itamar Medical Ltd. ITMR	28.7 M	-	0.03 %	$ 1.58 B	Israel
Electromed ELMD	50 M	$ 24.79	0.53 %	$ 210 M	USA
Misonix, Inc. MSON	43.7 M	-	-	$ 462 M	USA
Neovasc NVCN	1.99 M	-	-	$ 111 M	Canada
Intersect ENT, Inc. XENT	50.2 M	-	-	$ 955 M	USA
Sintx Technologies SINT	461 K	$ 2.5	-2.34 %	$ 6.93 M	USA
Cytosorbents Corporation CTSO	25.1 M	$ 0.61	-9.18 %	$ 33.2 M	USA
Aethlon Medical AEMD	1.36 M	$ 2.37	2.16 %	$ 3.7 M	USA
BIOLASE BIOL	16.7 M	-	-13.19 %	$ 166 K	USA
Smith & Nephew plc SNN	4.05 B	$ 32.54	0.28 %	$ 23.8 B	Britain
LivaNova PLC LIVN	940 M	$ 64.75	2.29 %	$ 3.53 B	Britain
InspireMD NSPR	2.65 M	$ 1.74	-0.57 %	$ 112 M	Israel
Sensus Healthcare SRTS	11.9 M	$ 4.13	-2.13 %	$ 67.4 M	USA
AdaptHealth Corp. AHCO	89.3 M	$ 11.58	1.67 %	$ 1.56 B	USA